Respiratory medicineHumansAmikacinMaleFemaleRetrospective Studies
Real-world effectiveness and lung abnormalities associated with amikacin liposome inhalation suspension.
Nozomi Tokita, Masashi Ito, Naohisa Urabe, Keiji Fujiwara, Koji Furuuchi, Tatsuya Kodama, Takashi Ohe, Atsuko Kurosaki, Yoshiaki Tanaka, Takashi Yoshiyama, Kazuma Kishi, Ken Ohta, Kozo Morimoto
Published: 202510.1016/j.rmed.2025.108408
Abstract
BACKGROUND: The guideline recommends the addition of amikacin liposome inhalation suspension (ALIS) for patients with refractory Mycobacterium avium complex pulmonary disease (MAC-PD). However, factors influencing culture conversion and managing ALIS…
Preview only. Read the full abstract at the source